Volume | 185,356 |
|
|||||
News | - | ||||||
Day High | 3.74 | Low High |
|||||
Day Low | 3.35 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.35 | 3.35 | 3.74 | 3.47 | 3.372 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
696 | 185,356 | $ 3.52 | $ 653,219 | - | 1.56 - 3.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:41:39 | 3 | $ 3.57 | USD |
ARCA Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
38.14M | 14.50M | - | 0 | -5.34M | -0.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ARCA Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.30 | 3.74 | 3.19 | 3.30 | 35,965 | 0.17 | 5.15% |
1 Month | 3.29 | 3.75 | 3.12 | 3.37 | 180,144 | 0.18 | 5.47% |
3 Months | 1.66 | 3.88 | 1.57 | 3.23 | 1,549,648 | 1.81 | 109.04% |
6 Months | 1.83 | 3.88 | 1.56 | 3.20 | 738,260 | 1.64 | 89.62% |
1 Year | 2.09 | 3.88 | 1.56 | 3.17 | 378,309 | 1.38 | 66.03% |
3 Years | 3.26 | 3.90 | 1.56 | 2.96 | 225,605 | 0.21 | 6.44% |
5 Years | 13.80 | 22.00 | 1.56 | 6.99 | 365,089 | -10.33 | -74.86% |
ARCA Biopharma Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |